Nateglinide
SIGMA/N3538 - ≥98% (HPLC), solid
Synonym: Fastic; N-
CAS Number: 105816-04-4
Empirical Formula (Hill Notation): C19H27NO3
Molecular Weight: 317.42
MDL Number: MFCD00875706
Linear Formula: C19H27NO3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | solid |
| InChI | 1S/C19H27NO3/c1-13(2)15-8 |
| InChI key | OELFLUMRDSZNSF-BRWVUGGUSA |
| originator | Novartis |
| Quality Level | 100  |
| SMILES string | CC(C)[C@@H]1CC[C@H](CC1)C |
| solubility | DMSO: >5 mg/mL |
| H2O: insoluble | |
| storage temp. | room temp |
| Biochem/physiol Actions: | Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. |
| Biochem/physiol Actions: | Nateglinide is a Kir6.2/SUR1 channel inhibitor and antidiabetic. It is selective for the SUR1 subtype, which is found on pancreatic islet cells. Nateglinide evokes KATP channel-dependent insulin secretion (50-200 μM) in the absence and presence of insulin. |
| Biochem/physiol Actions: | Nateglinide is a short-acting insulin secretagogue useful in treating type 2 diabetes. It is an insulinotropic agent effective for postprandial hyperglycemia. Nateglinide restores prandial insulin levels in a glucose-dependent manner. |
| Features and Benefits: | This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |